Skip to main content

People In The News: Feb 25, 2011

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Paul Berg will retire from his post on Affymetrix's board of directors in May, the company said this week. Berg has served on the company's board since 1993.


The Scripps Research Institute has named Michael Marletta to succeed long-time Scripps President Richard Lerner, who plans to continue his research at the institute after stepping down from the lead position. Marletta formerly was chair of the Department of Chemistry and a professor in the Department of Molecular and Cell Biology at The University of California, Berkeley, and he is a former MacArthrur Fellowship winner. Lerner has led the institute for 25 years.


University of California, San Francisco genetic professor Charles Epstein died on February 15 at the age of 77. Epstein's research covered a range of areas, but it emphasized the cellular and biochemical aspects of genetic disorders. One disorder he focused on is Down syndrome – for which he and his research team developed the first rodent model, enabling researchers to begin to study the genes and proteins involved in the syndrome. UCSF has already inaugurated the Charles J. Epstein Chair in Human Genetics and Pediatrics.


The White House this week appointed Olufunmilayo Falusi Olopade to serve on the National Cancer Advisory Board. Olopade is director of the University of Chicago's Center for Clinical Cancer Genetics and its Cancer Risk Clinic. Also a genetics professor and associate dean for Global Health at the school, Olopade has focused her research on cancer risk assessment, prevention, and individualized treatment based on risk factors and quality of life.


SRI International has hired Dave Anderson and William Thomsen to work in its Center for Advanced Drug Research (CADRE). Anderson, who formerly was senior director of proteomics at Catalyst Biosciences, will be principal scientist in CADRE's proteomics group. Thomsen, who previously was director of molecular pharmacology at Arena Pharmaceuticals, will be principal scientist in CADRE's metabolic diseases group.


Cardio3 Biosciences has appointed Jan Andersson and Louise Proulx to its board of directors. Andersson is VP of the Karolinska Institute and is a professor of infectious diseases at Karolinska University Hospital. Proulx is VP of R&D at Vertex Pharmaceuticals, and she is a member of the board of directors at Genome Quebec and the Canada Foundation for Innovation.


Robert Saul has been named chair of the American Academy of Pediatrics Committee on Genetics. Saul is a senior clinical geneticist at the Greenwood Cancer Center, where his work as focused on genetic disorders such as Fragile X syndrome.


Raymond Woosley, president, CEO, and board chairman of the Critical Path Institute, will retire from his position as president on Jan. 31, 2012. The institute's board is currently recruiting for someone to fill this post. Woosley has said he plans to remain involved in C-Path. After his retirement as president, he will continue serving on the board of directors and leading C-Path’s Arizona Center for Education and Research on Therapeutics.


Promoted? Changing jobs? GenomeWeb wants to know. E-mail HYPERLINK "mailto:[email protected]" [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.